ReviewDiagnostics (Basel, Switzerland)2021
Renal Complications Related to Checkpoint Inhibitors: Diagnostic and Therapeutic Strategies.
Review in Diagnostics (Basel, Switzerland), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 1 synthesis or guideline pooled it, 17 citations in OpenAlex.
- Immune checkpoint inhibitor-associated acute kidney injury in patients with cancer: a systematic review and meta-analysis of risk factors.Clinical and experimental nephrology · 2023Pooled it
- Pivotal role for typing of renal infiltrates: kidney localisation of a lymphoma presenting as pembrolizumab-associated nephritis. A lesson for the clinical nephrologist.Journal of nephrology · 2025Article
- Nephrotoxicity of Immune Checkpoint Inhibitors in Single and Combination Therapy-A Systematic and Critical Review.Biomedicines · 2025Review
- Case Report: Dialysis following sintilimab-induced stage 3 acute kidney injury: mechanism investigation and management strategies.Frontiers in oncology · 2025Article
- The differentiation and intervention strategies for acute kidney injury after or induced by immune checkpoint inhibitors.American journal of cancer research · 2025Review
- Renal involvement in solid cancers: epidemiological, clinical and histological characteristics study of 154 onconephrology patients.BMC nephrology · 2024Article
- Single and combination immunotherapy with chemotherapy and the risk of AKI in patients with solid cancer.Clinical and experimental nephrology · 2024Article
- New Challenges in the Diagnosis of Kidney Damage Due to Immune Checkpoint Inhibitors Therapy: An Observational Clinical Study.Diagnostics (Basel, Switzerland) · 2023Article
- [Basic nephropathology for pathologists-part 2 : Non-inflammatory lesions].Pathologie (Heidelberg, Germany) · 2023Article
- Immunotherapies and Renal Injury.Current opinion in toxicology · 2022Article
- Current Strategies for Tumor Photodynamic Therapy Combined With Immunotherapy.Frontiers in oncology · 2021Review
- Immune Checkpoint Inhibitors and the Heart.Frontiers in cardiovascular medicine · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Immune checkpoint inhibitors (ICI) targeting CTLA-4 and the PD-1/PD-L1 axis have unprecedentedly improved global prognosis in several types of cancers. However, they are associated with the occurrence of immune-related adverse events. Despite their low incidence, renal complications can interfere with the oncologic strategy. The breaking of peripheral tolerance and the emergence of auto- or drug-reactive T-cells are the main pathophysiological hypotheses to explain renal complications after ICI exposure. ICIs can induce a large spectrum of renal symptoms with variable severity (from isolated electrolyte disorders to dialysis-dependent acute kidney injury (AKI)) and presentation (acute tubule-interstitial nephritis in >90% of cases and a minority of glomerular diseases). In this review, the current trends in diagnosis and treatment strategies are summarized. The diagnosis of ICI-related renal complications requires special steps to avoid confounding factors, identify known risk factors (lower baseline estimated glomerular filtration rate, proton pump inhibitor use, and combination ICI therapy), and prove ICI causality, even after long-term exposure (weeks to months). A kidney biopsy should be performed as soon as possible. The treatment strategies rely on ICI discontinuation as well as co-medications, corticosteroids for 2 months, and tailored immunosuppressive drugs when renal response is not achieved.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.